Calamos Advisors LLC cut its stake in shares of St. Jude Medical Inc. (NYSE:STJ) by 39.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,968 shares of the medical technology company’s stock after selling 23,902 shares during the period. Calamos Advisors LLC’s holdings in St. Jude Medical were worth $2,806,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Sphinx Trading LP acquired a new position in shares of St. Jude Medical during the second quarter valued at about $107,000. IFP Advisors Inc raised its position in shares of St. Jude Medical by 14.8% in the first quarter. IFP Advisors Inc now owns 2,555 shares of the medical technology company’s stock valued at $141,000 after buying an additional 330 shares during the period. Checchi Capital Advisers LLC raised its position in shares of St. Jude Medical by 2.8% in the second quarter. Checchi Capital Advisers LLC now owns 2,332 shares of the medical technology company’s stock valued at $182,000 after buying an additional 64 shares during the period. QUANTRES ASSET MANAGEMENT Ltd acquired a new position in shares of St. Jude Medical during the second quarter valued at about $203,000. Finally, Capital Investment Advisors LLC acquired a new position in shares of St. Jude Medical during the second quarter valued at about $211,000. 81.59% of the stock is currently owned by hedge funds and other institutional investors.
Shares of St. Jude Medical Inc. (NYSE:STJ) traded up 0.50% on Monday, reaching $80.16. The company’s stock had a trading volume of 1,381,402 shares. The company’s 50-day moving average is $79.82 and its 200 day moving average is $74.66. St. Jude Medical Inc. has a 12-month low of $48.83 and a 12-month high of $84.00. The company has a market capitalization of $22.84 billion, a price-to-earnings ratio of 34.85 and a beta of 1.16.
St. Jude Medical (NYSE:STJ) last announced its quarterly earnings results on Wednesday, July 20th. The medical technology company reported $1.06 EPS for the quarter, meeting analysts’ consensus estimates of $1.06. St. Jude Medical had a return on equity of 27.60% and a net margin of 11.40%. The company earned $1.56 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same period in the prior year, the company earned $1.07 earnings per share. The firm’s revenue was up 10.8% on a year-over-year basis. Equities analysts anticipate that St. Jude Medical Inc. will post $4.06 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be paid a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.55%. The ex-dividend date of this dividend is Wednesday, September 28th. St. Jude Medical’s payout ratio is 53.91%.
Several equities analysts have issued reports on the company. Zacks Investment Research raised St. Jude Medical from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Tuesday, June 21st. Wedbush lowered St. Jude Medical from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $70.00 to $84.00 in a research note on Friday, July 15th. Barclays PLC reissued an “equal weight” rating and issued a $83.00 price target on shares of St. Jude Medical in a research note on Monday, August 15th. Jefferies Group reissued a “hold” rating and issued a $60.00 price target on shares of St. Jude Medical in a research note on Monday, September 12th. Finally, Argus reaffirmed a “hold” rating on shares of St. Jude Medical in a research report on Sunday, August 28th. Twenty-one analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $74.68.
St. Jude Medical Company Profile
St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.
Want to see what other hedge funds are holding STJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for St. Jude Medical Inc. (NYSE:STJ).
Receive News & Ratings for St. Jude Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St. Jude Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.